Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
Benet Pera(Consejo Superior de Investigaciones Científicas), Peter Martin(Northwestern University), Richard R. Furman(Cornell University), Rossella Marullo(Regeneron (United States)), John P. Leonard(New York University), Jia Ruan(Cornell University), Leandro Cerchietti(Cornell University), Haelee Ahn(NewYork–Presbyterian Hospital), Rebecca Elstrom(Acentech (United States)), Jayeshkumar Patel(Cornell University), ShaoNing Yang(Northwestern University), Tiffany Tang(NewYork–Presbyterian Hospital)
Cited by 50
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k